71083-14-2

Usage

Uses

Used in Pharmaceutical Industry:
6-Fluoroquinoline-3-carboxylic acid ethyl ester is used as a key intermediate for the synthesis of various drugs and pharmaceutical products, leveraging its antimicrobial and antitumor properties to develop new therapeutic agents.
Used in Medicinal Chemistry Research:
This chemical compound is employed as an important reagent in medicinal chemistry research, contributing to the discovery and development of novel organic compounds and therapeutic agents.
Used in Organic Synthesis:
6-Fluoroquinoline-3-carboxylic acid ethyl ester is utilized as a building block in the synthesis of organic compounds, playing a crucial role in the creation of new chemical entities with potential applications in various fields.

Upstream product

• 77779-49-8 4-chloro-6-fluoroquinoline-3-carboxylic acid ethyl ester 
• 10601-80-6 ethyl 3,3-diethoxypropanoate 
• 395-81-3 5-fluoro-2-nitrobenzaldehyde 

Downstream Products

• 116293-90-4 ethyl 6-fluoroquinoline-3-carboxylic acid 

Relevant academic research and scientific papers

Visible light catalyzed synthesis of quinolines from (aza)-Morita-Baylis-Hillman adducts

A mild and efficient protocol for the synthesis of quinoline scaffolds from (aza)-MBH adducts under visible light catalysis has been established. The reaction involves visible light catalyzed generation of amidyl radicals from (aza)-MBH adducts followed by intramolecular radical cyclization. The reaction exhibits a wide substrate scope, good functional group tolerance and high regioselectivity. This is the first example of utilizing (aza)-MBH adducts for the generation of amidyl radicals and synthesizing aza-heterocycles under visible light photoredox catalyzed reaction conditions.

Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase

Nicotinamide N-methyltransferase (NNMT) is a fundamental cytosolic biotransforming enzyme that catalyzes the N-methylation of endogenous and exogenous xenobiotics. We have identified small molecule inhibitors of NNMT with >1000-fold range of activity and developed comprehensive structure-Activity relationships (SARs) for NNMT inhibitors. Screening of N-methylated quinolinium, isoquinolinium, pyrididium, and benzimidazolium/benzothiazolium analogues resulted in the identification of quinoliniums as a promising scaffold with very low micromolar (IC50 à 1 μM) NNMT inhibition. Computer-based docking of inhibitors to the NNMT substrate (nicotinamide)-binding site produced a robust correlation between ligand-enzyme interaction docking scores and experimentally calculated IC50 values. Predicted binding orientation of the quinolinium analogues revealed selective binding to the NNMT substrate-binding site residues and essential chemical features driving protein-ligand intermolecular interactions and NNMT inhibition. The development of this new series of small molecule NNMT inhibitors direct the future design of lead drug-like inhibitors to treat several metabolic and chronic disease conditions characterized by abnormal NNMT activity.

A one-step synthesis of 2,4-unsubstituted quinoline-3-carboxylic acid esters from o -nitrobenzaldehydes

A straightforward and efficient one-step procedure for the synthesis of 2,4-unsubstituted quinoline-3-carboxylic acid ethyl esters is described. The simple reductive cyclization is carried out by treating various substituted o-nitrobenzaldehydes with inex

TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS

There is provided compounds of formula (I) wherein W is an optionally substituted aryl or heteroaryl group, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15- lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR

This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.